

Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal)

Technology appraisal guidance

Published: 6 May 2025

www.nice.org.uk/guidance/ta1061

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of omaveloxolone for treating Friedreich's ataxia in people 16 years and over. This is because Biogen withdrew its evidence submission. NICE will review this decision if Biogen decides to make a new submission.

Information

If NHS organisations wish to consider omaveloxolone for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

ISBN: 978-1-4731-7004-9